Meguro Shiori, Akamatsu Taisuke, Matsushima Sayomi, Kosugi Isao, Kawasaki Hideya, Arai Yoshifumi, Baba Satoshi, Tsuchida Takashi, Shido Yoji, Suda Takafumi, Iwashita Toshihide
Department of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan.
Department of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan; Department of Respiratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan; Division of Respiratory Medicine, Shizuoka General Hospital, Aoi-ku, Shizuoka 420-8527, Japan.
Hum Pathol. 2017 Apr;62:187-198. doi: 10.1016/j.humpath.2016.12.024. Epub 2017 Jan 11.
Our aims were to identify pericyte-specific markers for the analysis of formalin-fixed, paraffin-embedded human tissue samples, and to characterize perivascular myoid cell neoplasms phenotypically. Previously identified pericyte markers failed to distinguish pericytes from other cellular types, such as vascular smooth muscle cells (vSMCs) and fibroblasts, in immunohistochemistry analysis. However, we compared gene expression profiles between pericytes, vSMCs, and fibroblasts, and performed human skin vasculature immunohistochemistry analysis, which led to the identification of myosin 1B (MYO1B) as a novel pericyte marker. Afterward, we investigated the expression levels of MYO1B and h-caldesmon (h-CD) in perivascular myoid cell neoplasms, angioleiomyomas (n=28), glomus tumors (n=23), and myopericytomas (n=3). Angioleiomyomas were shown to contain MYO1B-negative and h-CD-positive (MYO1BhCD) tumor cells, with vSMC features. Glomus tumors were predominantly composed of the MYO1BhCD tumor cells, with the intermediate features between pericytes and vSMCs, whereas MYO1BhCD tumor cells with pericytic features and/or the MYO1BhCD tumor cells with vSMC features were frequently found in these tumors. The perivascular concentric pattern of 2 myopericytoma cases was composed of MYO1BhCD tumor cells, whereas that of one myopericytoma contained MYO1BhCD tumor cells. These results indicate that the ability to distinguish between these cell types may allow us to understand the differentiation and origin of perivascular myoid cell neoplasms. This is the first study to identify cell properties of perivascular myoid cell neoplasms by using a pericyte-specific marker with considerably lower expression in vSMCs and fibroblasts.
我们的目标是鉴定用于分析福尔马林固定、石蜡包埋的人体组织样本的周细胞特异性标志物，并从表型上对血管周围肌样细胞瘤进行特征描述。在免疫组织化学分析中，先前鉴定出的周细胞标志物无法将周细胞与其他细胞类型区分开来，如血管平滑肌细胞（vSMC）和成纤维细胞。然而，我们比较了周细胞、vSMC和成纤维细胞之间的基因表达谱，并进行了人体皮肤血管免疫组织化学分析，这导致鉴定出肌球蛋白1B（MYO1B）作为一种新的周细胞标志物。随后，我们研究了血管周围肌样细胞瘤、血管平滑肌瘤（n = 28）、血管球瘤（n = 23）和肌周细胞瘤（n = 3）中MYO1B和h - 钙调蛋白（h - CD）的表达水平。血管平滑肌瘤显示含有MYO1B阴性和h - CD阳性（MYO1B⁻hCD⁺）的具有vSMC特征的肿瘤细胞。血管球瘤主要由MYO1B⁻hCD⁺肿瘤细胞组成，具有周细胞和vSMC之间的中间特征，而具有周细胞特征的MYO1B⁺hCD⁻肿瘤细胞和/或具有vSMC特征的MYO1B⁻hCD⁺肿瘤细胞在这些肿瘤中经常被发现。2例肌周细胞瘤的血管周围同心模式由MYO1B⁺hCD⁻肿瘤细胞组成，而1例肌周细胞瘤则含有MYO1B⁻hCD⁺肿瘤细胞。这些结果表明，区分这些细胞类型的能力可能使我们能够了解血管周围肌样细胞瘤的分化和起源。这是第一项通过使用在vSMC和成纤维细胞中表达明显较低的周细胞特异性标志物来鉴定血管周围肌样细胞瘤细胞特性研究。
